244 related articles for article (PubMed ID: 38824253)
1. Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Leitch IM; Gerometta M; Eichenbaum D; Finger RP; Steinle NC; Baldwin ME
Ophthalmol Ther; 2024 Jul; 13(7):1857-1875. PubMed ID: 38824253
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
[TBL] [Abstract][Full Text] [Related]
3. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
5. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.
Yerramothu P
Vision (Basel); 2018 Jul; 2(3):. PubMed ID: 31735894
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
Khachigian LM; Liew G; Teo KYC; Wong TY; Mitchell P
J Transl Med; 2023 Feb; 21(1):133. PubMed ID: 36810060
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
9. Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment.
Moon BH; Kim Y; Kim SY
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629185
[TBL] [Abstract][Full Text] [Related]
10. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
ElSheikh RH; Chauhan MZ; Sallam AB
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
[TBL] [Abstract][Full Text] [Related]
11. Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Hussain RM; Shaukat BA; Ciulla LM; Berrocal AM; Sridhar J
Drug Des Devel Ther; 2021; 15():2653-2665. PubMed ID: 34188445
[TBL] [Abstract][Full Text] [Related]
12. A hypothetical therapeutic effect of light peripheral panretinal photocoagulation in neovascular age-related macular degeneration.
Mansour AM; Tripathy K; Parodi MB
Med Hypothesis Discov Innov Ophthalmol; 2022; 11(3):137-143. PubMed ID: 37641639
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
14. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM; Ciulla TA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
[TBL] [Abstract][Full Text] [Related]
15. Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.
Tan CS; Ngo WK; Chay IW; Ting DS; Sadda SR
Clin Ophthalmol; 2022; 16():917-933. PubMed ID: 35368240
[TBL] [Abstract][Full Text] [Related]
16. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration.
Figueroa AG; Boyd BM; Christensen CA; Javid CG; McKay BS; Fagan TC; Snyder RW
Am J Med; 2021 Jan; 134(1):122-128.e3. PubMed ID: 32628915
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.
Fu Y; Zhang Z; Webster KA; Paulus YM
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540673
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.
Sophie R; Akhtar A; Sepah YJ; Ibrahim M; Bittencourt M; Do DV; Nguyen QD
Biol Ther; 2012; 2(1):3. PubMed ID: 24392297
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
